Upgrade to SI Premium - Free Trial

Teva Pharma (TEVA): Downside From $16 Likely, Cutting PT - Cowen

October 4, 2017 9:28 AM
Cowen analyst, Ken Cacciatore, reiterated his Market Perform rating on shares of Teva Pharma (NYSE: TEVA) and cut his price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change

Next Articles